Navigation Links
Block Engineering Announces Collaborative Agreement with Pfizer for Next Generation Cleaning Verification Technology

MARLBOROUGH, Mass., Jan. 18, 2013 /PRNewswire/ -- Block Engineering, the leader in Quantum Cascade Laser (QCL) spectroscopy, announced today that it has signed a Collaborative Agreement with Pfizer, Inc. to develop a QCL-based system for real-time, noncontact Cleaning Verification of vessels during pharmaceutical manufacturing. The technology is based on Block's commercially available LaserScan (TM) Analyzer, which will be tailored to address the specific requirements of this application.

Accurate Cleaning Verification of vessels has a significant impact in pharmaceutical manufacturing, due to the potential health risks of cross-contamination between products. Today, in order to ensure that the walls of these vessels meet tough FDA cleanliness standards, swab-based techniques are applied to collect samples and bring them to off-line instruments, such as High Pressure Liquid Chromatography (HPLC) systems. These measurements typically take several hours or more per vessel during which the vessel usually remains idle. The key value proposition of the proposed technology is to eliminate this bottleneck and provide a handheld, battery-operated, barcode-scanner-like device capable of providing real-time, noncontact verification of the cleanliness of the vessel walls. Using the proposed technology, pharmaceutical manufacturing equipment could be scanned in a matter of minutes and potential areas that require additional cleaning will be identified in real-time without the need to take any samples. Block's device requires no consumables and utilizes next generation, eye-safe QCL-based infrared spectroscopy.

"Cleaning Verification is a critical step in the drug manufacturing process and Pfizer is committed to the development of technologies that could decrease inspection times, reduce costs and improve supply assurance," said Steve Hammond , Head of the Process Analytical Sciences Group (PASG) and Senior Director in the Global Manufacturing Services organization at Pfizer. "Block's groundbreaking technology fits well within Pfizer's Process Analytical Technology (PAT) initiatives and I look forward to working with them towards the development of this instrument."

The expected benefits of this novel approach include a reduction in the labor, material and consumables required today for swab-based verification. Furthermore, significant plant utilization increases can be achieved and drug supply assurances can be confidently offered. Key initiatives in the pharmaceutical industry today for Work-in-Progress inventory reduction and just-in-time-inventory implementation will significantly benefit from the proposed technology, as the manufacturing equipment idle time is reduced.

Petros Kotidis , CEO of Block Engineering commented, "I am very pleased to announce the strategic agreement with Pfizer towards the development of this breakthrough instrumentation. Block's QCL-based infrared spectrometers are opening new markets and Cleaning Verification is one of the most exciting and high impact applications. Pfizer's dominant and pioneering position in the introduction of next generation process analytical technologies will be a critical element in the success of this product."

The fundamental principle behind Block's technology and the currently commercially available LaserScan Analyzer is QCL-based infrared spectroscopy. When infrared light from the QCL reflects off of substances, it gets absorbed or reflected at rates that are absolutely unique to and characteristic of the substance. Therefore, when the reflected light is collected by the LaserScan's built-in detectors, a "fingerprint"-like pattern emerges, which contains all the necessary information for detection or analysis of the substance. Built-in libraries are typically used to pattern and provide real-time detection or analysis. Block's devices use unique QCLs, which cover the widest spectral range in the world within the 5-14 micron range and provide rapid sub-second, real-time measurements in handheld configurations.

About Block Engineering, LLC:
Founded in 1956, Block Engineering, LLC is a leading manufacturer and marketer of high performance Quantum Cascade Laser (QCL) and FTIR spectrometers for commercial, industrial, military and government customers. Block's Mobile Chemical Agent Detector (MCAD) system is a fixed site, passive FTIR spectrometer offered in partnership with Northrop Grumman Corp.  Block's PORTHOS (TM) is a portable, passive FTIR spectrometer system that remotely detects chemical threats as far as three miles and protects against chemical warfare agents and weapons of mass destruction. Block Engineering is also manufacturing and selling a line of unique QCL-based spectrometers, including the LaserScan Analyzer, for applications ranging from detection of explosives and liquid/solid chemical warfare agents to control of manufacturing operations and verification of surface conditions in a variety of industrial processes.

Block Engineering is located in Marlborough, Massachusetts, USA. For more information, visit

Contact: Scott Riggi , Vice President of Sales, 508-251-3105,

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit


SOURCE Block Engineering
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
2. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
3. Block Engineering Partners with SKAE and Pembroke for Quantum Cascade Laser Instrument Sales
4. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
5. Kentuckys PSE Blocking Technology Leading To Progress In Battle Against Meth
6. Missouris PSE Blocking Technology Leading To Progress In Battle Against Meth
7. Austen BioInnovation Institute in Akron Attracts Nationally Known Speakers For Conference on Value-driven Engineering, April 23-24
8. Nearly 300 Medical Device, Healthcare Professionals Attend First National Conference on Value-driven Engineering
9. Swiss Engineering for Surgical Perfection
10. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
11. American Oriental Bioengineering Announces Change of Independent Auditors
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... A simply groundbreaking television series, "Voices in America", which ... into an array of issues that are presently affecting Americans. Dedicated to providing the ... show is changing the subjects consumers focus on, one episode at a time. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... in central Michigan, have come together on Thanksgiving Day to share the things ... for viewing on the Serenity Point YouTube channel, patients displayed what they wrote ...
(Date:11/26/2015)... ... , ... The Catalent Applied Drug Delivery Institute today announced ... form selection in early phase drug development. The first of these is to ... the UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, ...
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
Breaking Medicine News(10 mins):